Starlynn Clarke

Senior Director, Preclinical Biology at Rondo Therapeutics, USA

Speaker

Starlynn Clarke, Ph.D. is Senior Director of Preclinical Biology at Rondo Therapeutics, an immuno-oncology company developing innovative bispecific antibodies for the treatment of solid tumors. At Rondo, she led the preclinical development of RNDO-564, a CD28-activating, Nectin-4–targeted bispecific antibody which entered the clinic in 2025 for treatment of bladder cancer. She also established a CD28 costimulatory antibody panel that underpins the company’s broader therapeutic pipeline.

With over a decade of experience in oncology and immunology drug discovery, Starlynn has deep expertise in multispecific antibody discovery as well as building and leading high-performing teams in startup environments. Previously, she held scientific roles at Frontier Medicines, Caribou Biosciences, and Teneobio. As a founding member of the Preclinical Biology team at Teneobio, she helped advance multiple bispecific antibody programs into clinical development.